These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34543098)

  • 1. Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis.
    Abdelwahab MT; Wasserman S; Brust JCM; Dheda K; Wiesner L; Gandhi NR; Warren RM; Sirgel FA; Meintjes G; Maartens G; Denti P
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0138121. PubMed ID: 34543098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.
    Wasserman S; Denti P; Brust JCM; Abdelwahab M; Hlungulu S; Wiesner L; Norman J; Sirgel FA; Warren RM; Esmail A; Dheda K; Gandhi NR; Meintjes G; Maartens G
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
    Garcia-Prats AJ; Schaaf HS; Draper HR; Garcia-Cremades M; Winckler J; Wiesner L; Hesseling AC; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002789. PubMed ID: 31039153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimen Simulation and Target Attainment Analysis.
    Alghamdi WA; Al-Shaer MH; An G; Alsultan A; Kipiani M; Barbakadze K; Mikiashvili L; Ashkin D; Griffith DE; Cegielski JP; Kempker RR; Peloquin CA
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32778547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India.
    Resendiz-Galvan JE; Arora PR; Abdelwahab MT; Udwadia ZF; Rodrigues C; Gupta A; Denti P; Ashavaid TF; Tornheim JA
    Front Pharmacol; 2022; 13():1081123. PubMed ID: 36686664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid Pharmacokinetics/Pharmacodynamics-Based Optimal Dosing for Multidrug-Resistant Tuberculosis.
    Zhou W; Nie W; Wang Q; Shi W; Yang Y; Li Q; Zhu H; Liu Z; Ding Y; Lu Y; Chu N
    Int J Antimicrob Agents; 2022 Jun; 59(6):106589. PubMed ID: 35405268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
    Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
    Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
    Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
    Chirehwa MT; Resendiz-Galvan JE; Court R; De Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Warren R; Maartens G; Denti P; McIlleron H
    Antimicrob Agents Chemother; 2023 Mar; 67(3):e0142622. PubMed ID: 36744891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
    Alffenaar JW; van Altena R; Harmelink IM; Filguera P; Molenaar E; Wessels AM; van Soolingen D; Kosterink JG; Uges DR; van der Werf TS
    Clin Pharmacokinet; 2010 Aug; 49(8):559-65. PubMed ID: 20608757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid for drug-resistant pulmonary tuberculosis.
    Singh B; Cocker D; Ryan H; Sloan DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012836. PubMed ID: 30893466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
    de Kock L; Sy SK; Rosenkranz B; Diacon AH; Prescott K; Hernandez KR; Yu M; Derendorf H; Donald PR
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6242-50. PubMed ID: 25114132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis.
    Hughes JA; Solans BP; Draper HR; Schaaf HS; Winckler JL; van der Laan L; Radtke KK; Fourie B; Wiesner L; Hesseling AC; Savic RM; Garcia-Prats AJ
    Clin Infect Dis; 2022 Nov; 75(10):1772-1780. PubMed ID: 35377434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.
    Bolhuis MS; Akkerman OW; Sturkenboom MGG; Ghimire S; Srivastava S; Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S327-S335. PubMed ID: 30496467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations.
    Garcia-Prats AJ; Rose PC; Hesseling AC; Schaaf HS
    Tuberculosis (Edinb); 2014 Mar; 94(2):93-104. PubMed ID: 24388605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis.
    Zhang H; He Y; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Alffenaar JW; Hu Y
    Front Pharmacol; 2022; 13():1032674. PubMed ID: 36699070
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.
    Alsaad N; Dijkstra JA; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Alffenaar JW
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3942-7. PubMed ID: 27067336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.
    Kamp J; Bolhuis MS; Tiberi S; Akkerman OW; Centis R; de Lange WC; Kosterink JG; van der Werf TS; Migliori GB; Alffenaar JC
    Int J Antimicrob Agents; 2017 Jun; 49(6):688-694. PubMed ID: 28389352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.